Cancer-induced cystatin C prevents complement-mediated synaptic loss through TREM2-mediated microglial phenotype regulation, reducing C1q/C3 deposition and excessive pruning. This is clinically important but probably secondary to plaque remodeling plus microglial state change rather than a distinct mechanism. Synaptic biomarkers are noisy and slower-moving than amyloid PD markers, making mechanism proof difficult in humans.
Gut dysbiosis leads to LPS translocation, triggering intestinal and systemic inflammation via TLR4/MyD88/NF-κB signaling, promoting α-synuclein pathology. The peripheral gut barrier is the most viable intervention point, though CNS microglial TLR4 activation remains mechanistically tenuous. Best therapeutic approach: zonulin antagonists (larazotide) for gut barrier restoration combined with NLRP3 inflammasome inhibition rather than direct TLR4 blockade.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
BiomarkerUnspecified Mechanismneurodegeneration
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
3/11
dimensions won
Synaptic protection via microglial/compl
11/11
dimensions won
LPS-TLR4-NF-κB Signaling Cascade as Ther
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.58
0.82
Evidence
0.55
0.58
Novelty
0.50
0.55
Feasibility
0.60
0.70
Impact
0.65
0.75
Druggability
0.50
0.70
Safety
0.55
0.68
Competition
0.60
0.75
Data
0.55
0.55
Reproducible
0.52
0.52
KG Connect
0.50
0.50
Score Breakdown
Dimension
Synaptic protection via microg
LPS-TLR4-NF-κB Signaling Casca
Mechanistic
0.580
0.820
Evidence
0.550
0.580
Novelty
0.500
0.550
Feasibility
0.600
0.700
Impact
0.650
0.750
Druggability
0.500
0.700
Safety
0.550
0.680
Competition
0.600
0.750
Data
0.550
0.550
Reproducible
0.520
0.520
KG Connect
0.500
0.500
Evidence
Synaptic protection via microglial/complement normalization
No evidence citations yet
LPS-TLR4-NF-κB Signaling Cascade as Therapeutic Target
No evidence citations yet
Debate Excerpts
Synaptic protection via microglial/complement norm
# Critical Evaluation of Hypotheses: Cancer-Cystatin-C-TREM2 Pathway Beyond Amyloid
## Preliminary Methodological Concerns
Before evaluating individual hypotheses, several systemic issues constrain ...
Domain Expert
The key feasibility filter is the source paper itself. In the February 5, 2026 `Cell` paper, Li et al. report that peripheral cancer/CSPs reduced amyloid in `5xFAD` and `APP/PS1`, but “did not affect ...
Synthesizer
{"ranked_hypotheses":[{"title":"Anti-inflammatory microglial reprogramming via cystatin-C/TREM2 axis","description":"Systemic tumors secrete cystatin C which crosses the BBB via LRP1 and engages TREM2...
LPS-TLR4-NF-κB Signaling Cascade as Therapeutic Ta
4 rounds · quality: 1.00
Theorist
# Mechanistic Hypotheses: Gut-Brain Axis in Parkinson's Disease
---
## Hypothesis 1: LPS-Induced TLR4/NF-κB Signaling Cascade Drives α-Synuclein Pathology
**Proposed Mechanism:**
Gut dysbiosis in P...
Skeptic
# Critical Evaluation of Gut-Brain Axis Hypotheses in Parkinson's Disease
## Overarching Methodological Concerns (Applicable to All Hypotheses)
Before examining individual hypotheses, several fundam...
Domain Expert
# Gut-Brain Axis in Parkinson's Disease: Therapeutic Development Assessment
## Executive Summary
Of the four mechanistic hypotheses proposed, none survives the skeptic's critique unscathed. However,...
Synthesizer
{"ranked_hypotheses":[{"title":"LPS-TLR4-NF-κB Signaling Cascade as Therapeutic Target","description":"Gut dysbiosis leads to LPS translocation, triggering intestinal and systemic inflammation via TLR...